{"id":"NCT02301624","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis","officialTitle":"A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-12","primaryCompletion":"2019-01-15","completion":"2019-01-15","firstPosted":"2014-11-26","resultsPosted":"2020-02-05","lastUpdate":"2020-02-05"},"enrollment":117,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Refractory Generalized Myasthenia Gravis"],"interventions":[{"type":"BIOLOGICAL","name":"Eculizumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Eculizumab/Eculizumab","type":"EXPERIMENTAL"},{"label":"Placebo/Eculizumab","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).","primaryOutcome":{"measure":"Count Of Participants With Treatment-Emergent Adverse Events","timeFrame":"Day 1 (after dosing) through End of Study (Week 208)","effectByArm":[{"arm":"Eculizumab/Eculizumab","deltaMin":55,"sd":null},{"arm":"Placebo/Eculizumab","deltaMin":59,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":60,"countries":["United States","Argentina","Belgium","Brazil","Canada","Czechia","Denmark","Finland","Hungary","Italy","Japan","Netherlands","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["30767274","31115842","30905021","31698177","34590717","33796147","33329303","33229455","32700461","32426038","32189108"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":56},"commonTop":["Headache","Nasopharyngitis","Diarrhoea","Upper respiratory tract infection","Arthralgia"]}}